Clinical trials: in Morocco
Aortic Aneurysm, Abdominal, Aortic Aneurysm, Thoracoabdominal
Evaluation of the Bifurcated Multilayer Flow Modulator for the Treatment of Abdominal Aortic Aneurysm
The study purpose is to determine the safety and efficacy of the BMFM used for the endovascular treatment of aortic aneurysm involving iliac arteries.
- Trial name
- STREAMLINER (NCT03024554)
- Testing
- Implantation of the Bifurcated Multilayer Flow Modulator
- Where
- 7 sites in Belgium, Bulgaria and 3 more
- Volunteers
- 42 people
- Sponsor
- Cardiatis
Diabetes Mellitus, Type 2
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine.
- Trial name
- PIONEER TEENS (NCT04596631)
- Testing
- Oral semaglutide
- Where
- 97 sites in United States, Australia and 20 more
- Volunteers
- 132 people
- Sponsor
- Novo Nordisk A/S
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration.
- Trial name
- Operetta 2 (NCT05123703)
- Testing
- Ocrelizumab, Fingolimod
- Where
- 71 sites in United States, Argentina and 23 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Generalized Pustular Psoriasis
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
- Trial name
- GEMINI-2 (NCT05366855)
- Testing
- Double-blind 200 mg imsidolimab, Open-label 200 mg imsidolimab, Standard of Care (SOC)
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 42 people
- Sponsor
- Vanda Pharmaceuticals
Generalized Pustular Psoriasis
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
- Trial name
- GEMINI-1 (NCT05352893)
- Testing
- 750 mg Imsidolimab, 300 mg Imsidolimab
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 45 people
- Sponsor
- Vanda Pharmaceuticals
Multiple Sclerosis, Primary Progressive
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course.
- Trial name
- O'HAND (NCT04035005)
- Testing
- Ocrelizumab
- Where
- 155 sites in United States, Australia and 21 more
- Volunteers
- 1,013 people
- Sponsor
- Hoffmann-La Roche
Triple Negative Breast Neoplasms
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
- Trial name
- IMpassion132 (NCT03371017)
- Testing
- Atezolizumab, Gemcitabine, Capecitabine
- Where
- 124 sites in United States, Argentina and 26 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Sickle Cell Disease
A Study of IMR-687 in Subjects With Sickle Cell Disease
A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
- Trial name
- NCT04474314
- Testing
- IMR-687
- Where
- 49 sites in United States, Ghana and 11 more
- Volunteers
- 115 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
β Thalassemia
A Study of IMR-687 in Subjects With Beta Thalassemia
A Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia
- Trial name
- NCT04411082
- Testing
- IMR-687
- Where
- 36 sites in Denmark, France and 11 more
- Volunteers
- 122 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Multiple Sclerosis
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Primary Objective: To assess the effect of teriflunomide in comparison to placebo on disease activity measured by time to first clinical relapse after randomization in children and adolescents 10 to 17 years of age with relapsing…
- Trial name
- TERIKIDS (NCT02201108)
- Testing
- Teriflunomide
- Where
- 57 sites in United States, Belgium and 20 more
- Volunteers
- 166 people
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy…
- Trial name
- TAIL (NCT03285763)
- Testing
- Atezolizumab
- Where
- 111 sites in Argentina, Brazil and 22 more
- Volunteers
- 619 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin Lymphoma
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC) administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL) (Induction and/or Maintenance treatment plus 24…
- Trial name
- NCT02406092
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 13 sites in Algeria, Morocco and 1 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting
This study is to characterize the use of tofacitinib after use of rituximab in patients with Rheumatoid Arthritis in a real-world setting.
- Trial name
- NCT05487703
- Where
- Morocco
- Volunteers
- 318 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
OPTIMISE is designed to provide knowledge regarding the use of Sunitinib as 1st line treatment and 2nd line treatment selected (Sunitinib-different sequence) with respect to efficacy outcomes, adverse events, and health related…
- Trial name
- OPTIMISE (NCT03140176)
- Testing
- Sunitinib
- Where
- 8 sites in Algeria, Egypt and 2 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Triple-Negative Breast Cancer
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
This Phase 3, multicenter, randomized, double-blind, placebo controlled study is designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-programmed death-ligand 1 [PD-L1] antibody) administered in…
- Trial name
- IMpassion131 (NCT03125902)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Paclitaxel
- Where
- 161 sites in United States, Argentina and 22 more
- Volunteers
- 653 people
- Sponsor
- Hoffmann-La Roche
HIV Infection
Strategic Timing of Antiretroviral Treatment
Objectives: To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high…
- Trial name
- START (NCT00867048)
- Testing
- All licensed antiretroviral medications
- Where
- 218 sites in United States, Argentina and 34 more
- Volunteers
- 4,688 people
- Sponsor
- University of Minnesota
HIV Infections
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy.
- Trial name
- ESPRIT (NCT00004978)
- Testing
- Recombinant interleukin-2 (rIL-2)
- Where
- 248 sites in United States, Argentina and 23 more
- Volunteers
- 4,150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
The purpose of this study is to determine the effect of short cycles of recombinant interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in HIV infected patients.
- Trial name
- STALWART (NCT00110812)
- Testing
- IL-2
- Where
- 36 sites in United States, Argentina and 9 more
- Volunteers
- 267 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
Study to evaluate patient preference of deferasirox film-coated tablet (FCT) or deferasirox dispersible tablet (DT) in patient with transfusion - dependent thalassemia or non-transfusion -dependent thalassemia as measured by…
- Trial name
- Jupiter (NCT02993224)
- Testing
- Deferasirox dispersable tablet (DT), Deferasirox film coated tablet (FCT)
- Where
- 17 sites in Egypt, Lebanon and 5 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents…
- Trial name
- Ellipse™ (NCT01541215)
- Testing
- liraglutide, metformin
- Where
- 185 sites in United States, Australia and 34 more
- Volunteers
- 135 people
- Sponsor
- Novo Nordisk A/S